GoldenGolden
WuXi Biologics

WuXi Biologics

WuXi Biologics is an open-access biologics technology platform offering solutions for discovery, development and manufacturing from concept to commercial manufacturing.

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a global open-access biologics technology platform offering end-to-end solutions for organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. As of June 30, 2019, there are a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore and US exceeding 280,000 liters by 2022.

History

Originally established in 2010 as one of the WuXi AppTec business units, they supported the biologics industry by offering cell line development and analytical protein characterization services. In 2015, WuXi Biologics was incorporated and in June 2017, WuXi Biologics went public on the Hong Kong Stock Exchange (HKEX) becoming one of the top 10 IPOs on the HKEX that year.

COVID-19 Response

On February 25, 2020, WuXi Biologics and Vir Biotechnology announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19).

Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Vir’s proprietary antibodies. WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. If the antibodies receive regulatory approvals, WuXi Biologics has the rights to commercialize therapies in Greater China, and Vir has the rights to commercialize therapies in all other markets worldwide.

Vir has identified a number of monoclonal antibodies (mAbs) that bind to SARS-CoV-2. These antibodies were isolated from individuals who had survived a Severe Acute Respiratory Syndrome (SARS) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

Timeline

February 9, 2021
WuXi Biologics announced that its MFG5 Drug Substance (DS) manufacturing facility in China has successfully launched GMP operation, with the capacity of 36,000L, deploying nine 4,000L single-use bioreactors.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

WuXi Biologics Overview

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
WuXi Biologics
April 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been...
WuXi Biologics
February 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the...
WuXi Biologics
February 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that its MFG5...
WuXi Biologics
December 28, 2020
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has...
WuXi Biologics
December 23, 2020
www.prnewswire.com:443
/PRNewswire/ -WuXi Biologics ("WuXi Bio") (2269.HK), ein weltweit tätiges Unternehmen mit einer Open-Access-Technologieplattform für Biologika, und Bayer haben...
WuXi Biologics
December 23, 2020
www.prnewswire.com:443
- WuXi Biologics adquiere la instalación de sustancias farmacéuticas en Wuppertal, Alemania, de Bayer Se espera que la instalación DS (MFG19) con perfusión...
WuXi Biologics
December 23, 2020
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics (« WuXi Bio ») (2269.HK), une entreprise mondiale disposant de plates-formes technologiques biologiques à accès libre de premier...
WuXi Biologics
December 21, 2020
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Bayer, today announced an...
WuXi Biologics
December 2, 2020
www.prnewswire.com:443
/PRNewswire/ -- Tubulis, WuXi STA and WuXi Biologics today announced a strategic collaboration to manufacture and advance Tubulis' next generation...
WuXi Biologics
November 20, 2020
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced its biologics...
Reportlinker
November 17, 2020
www.prnewswire.com:443
/PRNewswire/ -- The global biologics CDMO market (henceforth, referred to as the market studied) was valued at USD 8.89 billion in 2019, and it is expected to...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.